Document is current
Any future updates will be listed below
-
Authors
Ogdie, Alexis
Middaugh, Nicole
Marchese, Maya
Walsh, Jessica A.
Bello, Natalia
Ngantcha, Marcus
Kronbergs, Andris
Grace, Elsie L.
Mease, Philip J.
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 7 October 2025
Accepted: 6 February 2026
First Online: 12 March 2026
Declarations
:
: Alexis Ogdie: Grant/research support from AbbVie, Amgen, Janssen, Novartis, and Pfizer; consultancy fees from AbbVie, Amgen, BMS, Celgene, CorEvitas, Eli Lilly, GSK, Gilead, Janssen, Novartis, Pfizer, Takeda, and UCB, Nicole Middaugh and Maya Marchese: declare funding from Eli Lilly and Company for the research study and are employees of CorEvitas, LLC, Jessica A. Walsh: Consultant for/grant support from AbbVie, Amgen, Eli Lilly, Janssen, Merck, Novartis, Pfizer, and UCB, Natalia Bello, Marcus Ngantcha, Andris Kronbergs, and Elsie L. Grace: are employees and shareholders of Eli Lilly and Company, Philip J. Mease: Research grants from AbbVie, Acelyrin, Amgen, BMS, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Sun Pharma and UCB; consultancy fees from AbbVie, Acelyrin, Aclaris, Amgen, BMS, Boehringer Ingelheim, Celgene, Eli Lilly, Galapagos, Gilead, GSK, Janssen, Moonlake Pharma, Novartis, Pfizer, Sun Pharma, Takeda, UCB, and Ventyx; speakers’ bureau for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and, UCB.
: The study was performed in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practice. All participating investigators were required to obtain full board approval for conducting non-interventional research involving human subjects with a limited dataset. Sponsor approval and continuing review were obtained through a central institutional review board (IRB), the New England Independent Review Board (NEIRB; no. 120160939). For academic investigative sites that did not receive authorization to use the central IRB, full board approval was obtained from their respective governing IRBs, and documentation of approval was submitted to CorEvitas, LLC before the site’s participation and initiation of any study procedures. All patients in the registry were required to provide written informed consent and authorization before participating. Access and use of data from the PsA/SpA Registry for this study was authorized by CorEvitas, LLC.
